Cellbxhealth PLC — RNS

Regulatory news across CLBX

Date	Time	Date	TitleTitle (filtered)	Source
14/08/20	07:00:03	14 Aug 2020	Parsortix use to assess response to immunotherapy	Parsortix use to assess response to immunotherapy	RNS
06/08/20	12:20:13	6 Aug 2020	Holding(s) in Company	Holding(s) in Company	RNS
05/08/20	07:00:05	5 Aug 2020	Notice of AGM and Posting of Annual Report	Notice of AGM and Posting of Annual Report	RNS
20/07/20	07:00:05	20 Jul 2020	Study: Parsortix use in metastatic breast cancer	Study: Parsortix use in metastatic breast cancer	RNS
08/07/20	17:35:05	8 Jul 2020	Holding(s) in Company	Holding(s) in Company	RNS
08/07/20	17:30:10	8 Jul 2020	Holding(s) in Company	Holding(s) in Company	RNS
08/07/20	17:30:05	8 Jul 2020	Holding(s) in Company	Holding(s) in Company	RNS
25/06/20	07:00:07	25 Jun 2020	Preliminary Results	Preliminary Results	RNS
22/06/20	07:00:08	22 Jun 2020	Blood donations recommenced for FDA studies	Blood donations recommenced for FDA studies	RNS
29/05/20	07:00:08	29 May 2020	Notice of Results	Notice of Results	RNS
12/05/20	07:00:04	12 May 2020	CTC potential as biomarker in MET inhibitor trials	CTC potential as biomarker in MET inhibitor trials	RNS
04/05/20	07:00:06	4 May 2020	Leading cancer centre publishes Parsortix workflow	Leading cancer centre publishes Parsortix workflow	RNS
28/04/20	07:00:07	28 Apr 2020	Business Update	Business Update	RNS
17/04/20	07:00:04	17 Apr 2020	Parsortix performance in head and neck cancer	Parsortix performance in head and neck cancer	RNS
31/03/20	08:00:07	31 Mar 2020	COVID-19 BUSINESS IMPACT UPDATE	COVID-19 BUSINESS IMPACT UPDATE	RNS
03/03/20	07:00:06	3 Mar 2020	Assessing risk of brain metastasis in lung cancer	Assessing risk of brain metastasis in lung cancer	RNS
27/02/20	07:00:12	27 Feb 2020	Parsortix outperforms other CTC systems in RCC	Parsortix outperforms other CTC systems in RCC	RNS
25/02/20	07:00:07	25 Feb 2020	ANGLE announce Tri-Con presentation with BioView	ANGLE announce Tri-Con presentation with BioView	RNS
17/02/20	07:00:06	17 Feb 2020	Data demonstrates key advantages of Parsortix	Data demonstrates key advantages of Parsortix	RNS
11/02/20	07:00:08	11 Feb 2020	Study demonstrates Parsortix potential in melanoma	Study demonstrates Parsortix potential in melanoma	RNS
03/02/20	09:10:43	3 Feb 2020	Issue of Equity	Issue of Equity	RNS
30/01/20	07:00:12	30 Jan 2020	Interim Results	Interim Results	RNS
30/01/20	07:00:07	30 Jan 2020	Change of accounting reference date	Change of accounting reference date	RNS
22/01/20	07:00:03	22 Jan 2020	Successful face-to-face meeting with FDA	Successful face-to-face meeting with FDA	RNS
08/01/20	12:33:31	8 Jan 2020	Notice of Results	Notice of Results	RNS
23/12/19	09:55:50	23 Dec 2019	Issue of Equity	Issue of Equity	RNS
07/11/19	07:00:15	7 Nov 2019	Cancer centre shows Parsortix use in melanoma	Cancer centre shows Parsortix use in melanoma	RNS
30/10/19	14:44:02	30 Oct 2019	Result of AGM	Result of AGM	RNS
30/10/19	07:00:03	30 Oct 2019	Q-submission to FDA containing headline data	Q-submission to FDA containing headline data	RNS
08/10/19	08:00:10	8 Oct 2019	Notice of AGM	Notice of AGM	RNS
04/10/19	18:54:01	4 Oct 2019	Holding(s) in Company	Holding(s) in Company	RNS
04/10/19	08:00:05	4 Oct 2019	European patent granted for megakaryocyte analysis	European patent granted for megakaryocyte analysis	RNS
13/09/19	08:00:10	13 Sept 2019	Use of Parsortix in head and neck cancer	Use of Parsortix in head and neck cancer	RNS
10/09/19	08:00:10	10 Sept 2019	Research with Parsortix in prostate cancer	Research with Parsortix in prostate cancer	RNS
04/09/19	08:00:17	4 Sept 2019	Parsortix for Neuroendocrine Analysis in SCLC	Parsortix for Neuroendocrine Analysis in SCLC	RNS
29/08/19	08:00:03	29 Aug 2019	Initiation of Ovarian Cancer Study	Initiation of Ovarian Cancer Study	RNS
31/07/19	08:00:09	31 Jul 2019	Prelim Results for the year ended 30 April 2019	Prelim Results for the year ended 30 April 2019	RNS
22/07/19	08:00:06	22 Jul 2019	Use of Parsortix for single cell analysis of CTCs	Use of Parsortix for single cell analysis of CTCs	RNS
05/06/19	08:00:10	5 Jun 2019	Completion of Ovarian Cancer Pre-Study	Completion of Ovarian Cancer Pre-Study	RNS
31/05/19	08:00:03	31 May 2019	Positive Results from FDA Clinical Study	Positive Results from FDA Clinical Study	RNS
12/04/19	08:00:06	12 Apr 2019	LUNG CANCER STUDY USES ANGLE'S PARSORTIX SYSTEM	LUNG CANCER STUDY USES ANGLE'S PARSORTIX SYSTEM	RNS
04/04/19	08:00:05	4 Apr 2019	AACR 2019	AACR 2019	RNS
11/03/19	07:00:11	11 Mar 2019	Holding(s) in Company	Holding(s) in Company	RNS
07/03/19	07:00:13	7 Mar 2019	ENROLMENT COMPLETE FOR FDA CLINICAL STUDY	ENROLMENT COMPLETE FOR FDA CLINICAL STUDY	RNS
28/02/19	07:00:22	28 Feb 2019	FIRST SUBJECTS ENROLLED IN OVARIAN CANCER STUDY	FIRST SUBJECTS ENROLLED IN OVARIAN CANCER STUDY	RNS
25/02/19	07:00:06	25 Feb 2019	CUSTOMER DEMONSTRATES NEW USE FOR PARSORTIX	CUSTOMER DEMONSTRATES NEW USE FOR PARSORTIX	RNS
11/02/19	07:00:05	11 Feb 2019	Research into role of immune cells in cancer	Research into role of immune cells in cancer	RNS
31/01/19	07:00:09	31 Jan 2019	Interim Results	Interim Results	RNS
29/01/19	07:00:09	29 Jan 2019	NEW APPLICATION FOR PARSORTIX IN CANCER ANALYSIS	NEW APPLICATION FOR PARSORTIX IN CANCER ANALYSIS	RNS
11/01/19	14:05:58	11 Jan 2019	Second Price Monitoring Extn	Second Price Monitoring Extn	RNS

Showing 251–300 of 474 announcements